Home
About Us
FAQ
Contact Us
Media Tools
ExpertConnect App
MyExpertNet
University Partners
Becoming a Partner
Key Organizations
Search Assistance
Help
Expert Profile
Views:
137
Share
QR code
Edit Profile
Roberto Firpi-Morell
Professor
MD-GASTROENTERLOGY-LIVER | COLLEGE-MEDICINE
View:
Select
All (all in one)
Research Terms and Keywords
Publications
Co-Investigator Network
Websites
Contact
All
Research
Publications
Network
Websites
Contact
Research Terms & Keywords
Research Terms
Medical Sciences
Industries
Health Care
Research Projects
Ends
Title
08-2023
A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects
A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects
12-2022
A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis"
A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis"
08-2022
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
07-2021
An Open-Label, Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
An Open-Label, Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
04-2021
Merck MK5172-017 "A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/orViral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have BeenPreviously Treated with MK-5172 in a Prior Clinical Trial"
Merck MK5172-017 "A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/orViral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have BeenPreviously Treated with MK-5172 in a Prior Clinical Trial"
06-2020
AASLD 2019 NP/PA CLINICAL HEP0ATOLOGY FELLOWSHIP PROGRAM
AASLD 2019 NP/PA CLINICAL HEP0ATOLOGY FELLOWSHIP PROGRAM
04-2019
Conatus IDN-6556-07 A Multicenter, Double-Blind, Sponsor-Open Trial of IDN-6556 in Subjects Who had HCV Reinfection & Liver Fibrosis following Orthotopic Liver Transplantation for HCV Infection & Who Subsequently Achieved a SVR Following anti-HCV Therapy
Conatus IDN-6556-07 A Multicenter, Double-Blind, Sponsor-Open Trial of IDN-6556 in Subjects Who had HCV Reinfection & Liver Fibrosis following Orthotopic Liver Transplantation for HCV Infection & Who Subsequently Achieved a SVR Following anti-HCV Therapy
03-2019
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1, GT2, and GT4 Infection
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1, GT2, and GT4 Infection
10-2018
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection.
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection.
09-2017
BMSAI444-026 "An Open-Label Re-treatment Study with Peg-Interferon alfa-2a, Ribavirin and BMS-790052 With or Without BMS650032 for Subjects with Chronic Hepatitis C"
BMSAI444-026 "An Open-Label Re-treatment Study with Peg-Interferon alfa-2a, Ribavirin and BMS-790052 With or Without BMS650032 for Subjects with Chronic Hepatitis C"
09-2017
"AbbVie M14-490" An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic HCV Infection and Cirrhosis (TURQUOISE-III)
"AbbVie M14-490" An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic HCV Infection and Cirrhosis (TURQUOISE-III)
09-2017
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
06-2017
'MK5172-060: A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Na?ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection.
'MK5172-060: A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Na?ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection.
06-2017
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis
04-2017
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who Failed Prior Tx with Peg/RBV with HCV GT1, GT4, GT5, and GT6
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who Failed Prior Tx with Peg/RBV with HCV GT1, GT4, GT5, and GT6
04-2017
'MK5172-059 A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic HCV Infection with Advanced Cirrhosisand Child-Pugh (CP)-B Hepatic Insufficiency'
'MK5172-059 A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic HCV Infection with Advanced Cirrhosisand Child-Pugh (CP)-B Hepatic Insufficiency'
08-2016
BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
03-2016
An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
01-2016
A Phase 2 open-label study in patients with recurrent Genotype 1 hepAtitis C post-orthotopic Liver transplAnt to eXplore the safety and efficacY of simeprevir and sofosbuvir with and without ribavirin
A Phase 2 open-label study in patients with recurrent Genotype 1 hepAtitis C post-orthotopic Liver transplAnt to eXplore the safety and efficacY of simeprevir and sofosbuvir with and without ribavirin
10-2015
Abbott M11-646 'A Randomized, Double-blind, Placebo-controlled Study to Evaluate te Efficacy and Safety of ABT-450/Ritonivair/ABT-267 (ABT-450/R/ABT-267) and ABT-333 Co-administered with RBV in Treatment-Naive Adults with Geno 1 Chronic (HCV) '
Abbott M11-646 'A Randomized, Double-blind, Placebo-controlled Study to Evaluate te Efficacy and Safety of ABT-450/Ritonivair/ABT-267 (ABT-450/R/ABT-267) and ABT-333 Co-administered with RBV in Treatment-Naive Adults with Geno 1 Chronic (HCV) '
09-2015
GS-US-337-0102 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ? Ribavirin for 12 and 24 Weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV'
GS-US-337-0102 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ? Ribavirin for 12 and 24 Weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV'
06-2015
BMS AI447-028
BMS AI447-028
10-2014
P2938-0721 QUANTUM
P2938-0721 QUANTUM
04-2014
P7977-0724 ATOMIC
P7977-0724 ATOMIC
01-2014
COLO400A2430
COLO400A2430
02-2013
P7977-0422P7977-0422 A Multi-Center, Placebo-Controlled
P7977-0422P7977-0422 A Multi-Center, Placebo-Controlled
04-2012
FISSION: P7977-1231
FISSION: P7977-1231
01-2012
RNDMZ OPN-LBL COMPAR EVAL OF CONVERSION FROM CALCINEURIN
RNDMZ OPN-LBL COMPAR EVAL OF CONVERSION FROM CALCINEURIN
01-2011
Debio 025-HCV-207
Debio 025-HCV-207
08-2009
FibroScan
FibroScan
12-2008
Cyclosporine in Hep C Infection Viral Clearance
Cyclosporine in Hep C Infection Viral Clearance
07-2008
Comparison of PEG-Intron 1.5ug/kg/wk Plus REBETOL vs PEG
Comparison of PEG-Intron 1.5ug/kg/wk Plus REBETOL vs PEG
Publications
Search Google Scholar for Roberto Firpi-Morell
Co-Investigator Network
Virginia Clark
Program Director & Associate Professor
University of Florida
MD-GASTROENTERLOGY-LIVER, College-Medicine
clarkvc@medicine.ufl.edu
Carol Mathews
Psychiatry Chair & Professor
University of Florida
MD-PSYCHIATRY, College-Medicine
carolmathews@ufl.edu
Giuseppe Morelli
Clinical Professor
University of Florida
MD-GASTROENTERLOGY-LIVER, College-Medicine
morelgj@medicine.ufl.edu
David Nelson
Senior Vice President for Health Affairs, UF & President, UF Health
University of Florida
HA-EXECUTIVE, Office Of Health Affairs
nelsodr@ufl.edu
Inactive Expert
Peggy Parnell
Program Assistant
University of Florida
MD-GASTROENTERLOGY-LIVER, College-Medicine
-
Abhisheak Sharma
Assistant Director and Assistant Professor
University of Florida
PH-PHARMACEUTICS, College-Pharmacy
asharma1@ufl.edu
Michael Weaver
Professor
University of Florida
NR-BNS-BIOBEHAVORIAL NUR SCI, College-Nursing
michael.weaver@ufl.edu
Chengguo Xing
Professor and Associate Chair
University of Florida
PH-MEDICINAL CHEMISTRY, College-Pharmacy
chengguoxing@ufl.edu
Websites
Search Google Scholar for Roberto Firpi-Morell
Contact Information
roberto.firpi@medicine.ufl.edu
3522739477
PO Box 100214 GAINESVILLE, FL 32610-0214
Profile QR code
What is this?
Keyword Search
Please enter valid search criteria.
Search
Centers
Experts
Projects
Speakers
Stories
Technologies
Videos
University
All Universities
Florida A&M University
Florida Atlantic University
Florida Gulf Coast University
Florida Institute of Technology
Florida International University
Florida State University
University of Central Florida
University of Florida
University of Miami
University of North Florida
University of South Florida
University of West Florida
Browse by STEM
Biotechnology
Computer Science
Energy
Engineering
Environmental Sciences
Information Science
Life Sciences
Mathematics
Medical Sciences
Military Sciences
Natural Sciences
Physical Sciences
Plant Sciences
Science
Space Sciences
Technology
Transportation
